Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

CATX vs LNTH vs AGEN vs RNW vs EXAS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CATX
Perspective Therapeutics, Inc.

Medical - Devices

HealthcareAMEX • US
Market Cap$267M
5Y Perf.-74.3%
LNTH
Lantheus Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$5.92B
5Y Perf.+387.2%
AGEN
Agenus Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$132M
5Y Perf.-95.3%
RNW
ReNew Energy Global Plc

Renewable Utilities

UtilitiesNASDAQ • GB
Market Cap$1.33B
5Y Perf.-50.9%
EXAS
Exact Sciences Corporation

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$20.02B
5Y Perf.-24.1%

CATX vs LNTH vs AGEN vs RNW vs EXAS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CATX logoCATX
LNTH logoLNTH
AGEN logoAGEN
RNW logoRNW
EXAS logoEXAS
IndustryMedical - DevicesDrug Manufacturers - Specialty & GenericBiotechnologyRenewable UtilitiesMedical - Diagnostics & Research
Market Cap$267M$5.92B$132M$1.33B$20.02B
Revenue (TTM)$576K$1.55B$114M$129.66B$3.25B
Net Income (TTM)$-114M$279M$115K$11.97B$-208M
Gross Margin-150.2%60.5%35.7%77.9%69.7%
Operating Margin-184.6%18.8%-17.7%48.4%-6.4%
Forward P/E17.5x1.8x0.4x582.8x
Total Debt$4M$738K$10M$732.28B$2.52B
Cash & Equiv.$62M$359M$3M$40.42B$956M

CATX vs LNTH vs AGEN vs RNW vs EXASLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CATX
LNTH
AGEN
RNW
EXAS
StockFeb 21May 26Return
Perspective Therape… (CATX)10025.7-74.3%
Lantheus Holdings, … (LNTH)100487.2+387.2%
Agenus Inc. (AGEN)1004.7-95.3%
ReNew Energy Global… (RNW)10049.1-50.9%
Exact Sciences Corp… (EXAS)10075.9-24.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: CATX vs LNTH vs AGEN vs RNW vs EXAS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: LNTH and RNW are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. ReNew Energy Global Plc is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. EXAS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
CATX
Perspective Therapeutics, Inc.
The Income Pick

CATX is the clearest fit if your priority is income & stability.

  • Dividend streak 1 yrs, beta 1.58
Best for: income & stability
LNTH
Lantheus Holdings, Inc.
The Long-Run Compounder

LNTH has the current edge in this matchup, primarily because of its strength in long-term compounding and sleep-well-at-night.

  • 41.9% 10Y total return vs EXAS's 16.7%
  • Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
  • 18.0% margin vs CATX's -197.3%
  • 12.4% ROA vs CATX's -36.6%, ROIC 30.6% vs 5.2%
Best for: long-term compounding and sleep-well-at-night
AGEN
Agenus Inc.
The Value Angle

Among these 5 stocks, AGEN doesn't own a clear edge in any measured category.

Best for: healthcare exposure
RNW
ReNew Energy Global Plc
The Growth Play

RNW is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 19.4%, EPS growth 10.1%, 3Y rev CAGR 17.8%
  • 19.4% revenue growth vs CATX's -100.0%
  • Lower P/E (0.4x vs 582.8x)
Best for: growth exposure
EXAS
Exact Sciences Corporation
The Defensive Pick

EXAS ranks third and is worth considering specifically for defensive.

  • Beta 0.12, current ratio 2.43x
  • Beta 0.12 vs AGEN's 2.72
  • +96.9% vs RNW's -17.7%
Best for: defensive
See the full category breakdown
CategoryWinnerWhy
GrowthRNW logoRNW19.4% revenue growth vs CATX's -100.0%
ValueRNW logoRNWLower P/E (0.4x vs 582.8x)
Quality / MarginsLNTH logoLNTH18.0% margin vs CATX's -197.3%
Stability / SafetyEXAS logoEXASBeta 0.12 vs AGEN's 2.72
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)EXAS logoEXAS+96.9% vs RNW's -17.7%
Efficiency (ROA)LNTH logoLNTH12.4% ROA vs CATX's -36.6%, ROIC 30.6% vs 5.2%

CATX vs LNTH vs AGEN vs RNW vs EXAS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CATXPerspective Therapeutics, Inc.

Segment breakdown not available.

LNTHLantheus Holdings, Inc.
FY 2025
Product
33.4%$1.5B
Radiopharmaceutical Oncology
21.9%$989M
PYLARIFY
21.9%$989M
Total Precision Diagnostics
10.9%$493M
DEFINITY
7.3%$330M
Techne Lite
1.9%$87M
Strategic Partnerships And Other
1.3%$59M
Other (2)
1.3%$59M
AGENAgenus Inc.
FY 2025
Non Cash Royalty Revenue
99.1%$109M
Other
0.9%$1M
RNWReNew Energy Global Plc
FY 2024
Power
85.8%$81.6B
Sale of goods
13.9%$13.2B
Other Revenue
0.4%$350M
EXASExact Sciences Corporation
FY 2025
Screening
77.9%$2.5B
Precision Oncology
22.1%$717M

CATX vs LNTH vs AGEN vs RNW vs EXAS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLLNTHLAGGINGAGEN

Income & Cash Flow (Last 12 Months)

RNW leads this category, winning 4 of 6 comparable metrics.

RNW is the larger business by revenue, generating $129.7B annually — 225100.5x CATX's $576,000. LNTH is the more profitable business, keeping 18.0% of every revenue dollar as net income compared to CATX's -197.3%. On growth, RNW holds the edge at +37.2% YoY revenue growth, suggesting stronger near-term business momentum.

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
RevenueTrailing 12 months$576,000$1.5B$114M$129.7B$3.2B
EBITDAEarnings before interest/tax-$104M$347M-$10M$86.9B-$41M
Net IncomeAfter-tax profit-$114M$279M$115,000$12.0B-$208M
Free Cash FlowCash after capex-$112M$372M-$159M-$23.8B$357M
Gross MarginGross profit ÷ Revenue-150.2%+60.5%+35.7%+77.9%+69.7%
Operating MarginEBIT ÷ Revenue-184.6%+18.8%-17.7%+48.4%-6.4%
Net MarginNet income ÷ Revenue-197.3%+18.0%+0.1%+9.2%-6.4%
FCF MarginFCF ÷ Revenue-195.2%+24.0%-139.1%-18.4%+11.0%
Rev. Growth (YoY)Latest quarter vs prior year+1.2%+27.5%+37.2%+23.1%
EPS Growth (YoY)Latest quarter vs prior year-2.2%+76.5%+85.3%+94.8%+90.4%
RNW leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

Evenly matched — AGEN and RNW each lead in 2 of 6 comparable metrics.

At 26.7x trailing earnings, LNTH trades at a 43% valuation discount to RNW's 46.9x P/E. On an enterprise value basis, RNW's 11.3x EV/EBITDA is more attractive than CATX's 20.1x.

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
Market CapShares × price$267M$5.9B$132M$1.3B$20.0B
Enterprise ValueMkt cap + debt − cash$210M$5.6B$140M$8.6B$21.6B
Trailing P/EPrice ÷ TTM EPS-2.93x26.69x-1102.94x46.91x-95.37x
Forward P/EPrice ÷ next-FY EPS est.17.52x1.79x0.40x582.83x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple20.06x14.61x11.27x
Price / SalesMarket cap ÷ Revenue3.84x1.16x1.30x6.16x
Price / BookPrice ÷ Book value/share0.80x5.72x1.43x8.24x
Price / FCFMarket cap ÷ FCF16.73x56.10x
Evenly matched — AGEN and RNW each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

LNTH leads this category, winning 7 of 9 comparable metrics.

LNTH delivers a 24.3% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-43 for CATX. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RNW's 5.59x. On the Piotroski fundamental quality scale (0–9), EXAS scores 7/9 vs RNW's 4/9, reflecting strong financial health.

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
ROE (TTM)Return on equity-42.8%+24.3%+8.4%-8.7%
ROA (TTM)Return on assets-36.6%+12.4%+0.1%+1.2%-3.5%
ROICReturn on invested capital+5.2%+30.6%+4.9%-3.6%
ROCEReturn on capital employed+5.2%+17.1%+6.9%-4.0%
Piotroski ScoreFundamental quality 0–945647
Debt / EquityFinancial leverage0.01x0.00x5.59x1.05x
Net DebtTotal debt minus cash-$58M-$358M$7M$691.9B$1.6B
Cash & Equiv.Liquid assets$62M$359M$3M$40.4B$956M
Total DebtShort + long-term debt$4M$738,000$10M$732.3B$2.5B
Interest CoverageEBIT ÷ Interest expense-948.77x11.72x1.11x86.76x-5.47x
LNTH leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — LNTH and EXAS each lead in 3 of 6 comparable metrics.

A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $611 for AGEN. Over the past 12 months, EXAS leads with a +96.9% total return vs RNW's -17.7%. The 3-year compound annual growth rate (CAGR) favors EXAS at 15.2% vs AGEN's -51.0% — a key indicator of consistent wealth creation.

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
YTD ReturnYear-to-date+29.0%+35.3%+16.1%-7.8%+3.1%
1-Year ReturnPast 12 months+53.2%+13.1%+27.1%-17.7%+96.9%
3-Year ReturnCumulative with dividends-46.2%-4.0%-88.2%+4.4%+53.0%
5-Year ReturnCumulative with dividends-59.0%+314.2%-93.9%-45.7%+0.4%
10-Year ReturnCumulative with dividends-66.4%+4192.5%-94.3%-50.5%+1669.1%
CAGR (3Y)Annualised 3-year return-18.7%-1.4%-51.0%+1.5%+15.2%
Evenly matched — LNTH and EXAS each lead in 3 of 6 comparable metrics.

Risk & Volatility

EXAS leads this category, winning 2 of 2 comparable metrics.

EXAS is the less volatile stock with a 0.12 beta — it tends to amplify market swings less than AGEN's 2.72 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. EXAS currently trades 99.9% from its 52-week high vs AGEN's 51.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
Beta (5Y)Sensitivity to S&P 5001.58x0.47x2.72x0.62x0.12x
52-Week HighHighest price in past year$6.16$93.00$7.34$8.24$104.98
52-Week LowLowest price in past year$1.96$47.25$2.71$4.38$38.81
% of 52W HighCurrent price vs 52-week peak+58.4%+97.8%+51.1%+65.5%+99.9%
RSI (14)Momentum oscillator 0–10039.361.248.864.176.4
Avg Volume (50D)Average daily shares traded1.4M886K814K734K4.2M
EXAS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CATX and AGEN and RNW each lead in 1 of 1 comparable metric.

Analyst consensus: CATX as "Buy", LNTH as "Buy", AGEN as "Buy", RNW as "Buy", EXAS as "Buy". Consensus price targets imply 226.4% upside for CATX (target: $12) vs -1.6% for EXAS (target: $103).

MetricCATX logoCATXPerspective Thera…LNTH logoLNTHLantheus Holdings…AGEN logoAGENAgenus Inc.RNW logoRNWReNew Energy Glob…EXAS logoEXASExact Sciences Co…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$11.75$101.00$7.33$6.52$103.18
# AnalystsCovering analysts111711641
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises1011
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.1%+0.1%0.0%+0.1%
Evenly matched — CATX and AGEN and RNW each lead in 1 of 1 comparable metric.
Key Takeaway

RNW leads in 1 of 6 categories (Income & Cash Flow). LNTH leads in 1 (Profitability & Efficiency). 3 tied.

Best OverallLantheus Holdings, Inc. (LNTH)Leads 1 of 6 categories
Loading custom metrics...

CATX vs LNTH vs AGEN vs RNW vs EXAS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is CATX or LNTH or AGEN or RNW or EXAS a better buy right now?

For growth investors, ReNew Energy Global Plc (RNW) is the stronger pick with 19.

4% revenue growth year-over-year, versus -100. 0% for Perspective Therapeutics, Inc. (CATX). Lantheus Holdings, Inc. (LNTH) offers the better valuation at 26. 7x trailing P/E (17. 5x forward), making it the more compelling value choice. Analysts rate Perspective Therapeutics, Inc. (CATX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CATX or LNTH or AGEN or RNW or EXAS?

On trailing P/E, Lantheus Holdings, Inc.

(LNTH) is the cheapest at 26. 7x versus ReNew Energy Global Plc at 46. 9x. On forward P/E, ReNew Energy Global Plc is actually cheaper at 0. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — CATX or LNTH or AGEN or RNW or EXAS?

Over the past 5 years, Lantheus Holdings, Inc.

(LNTH) delivered a total return of +314. 2%, compared to -93. 9% for Agenus Inc. (AGEN). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus AGEN's -94. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CATX or LNTH or AGEN or RNW or EXAS?

By beta (market sensitivity over 5 years), Exact Sciences Corporation (EXAS) is the lower-risk stock at 0.

12β versus Agenus Inc. 's 2. 72β — meaning AGEN is approximately 2159% more volatile than EXAS relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — CATX or LNTH or AGEN or RNW or EXAS?

By revenue growth (latest reported year), ReNew Energy Global Plc (RNW) is pulling ahead at 19.

4% versus -100. 0% for Perspective Therapeutics, Inc. (CATX). On earnings-per-share growth, the picture is similar: Agenus Inc. grew EPS 100. 0% year-over-year, compared to -44. 7% for Perspective Therapeutics, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CATX or LNTH or AGEN or RNW or EXAS?

Lantheus Holdings, Inc.

(LNTH) is the more profitable company, earning 15. 2% net margin versus -197. 3% for Perspective Therapeutics, Inc. — meaning it keeps 15. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -184. 6% for CATX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CATX or LNTH or AGEN or RNW or EXAS more undervalued right now?

On forward earnings alone, ReNew Energy Global Plc (RNW) trades at 0.

4x forward P/E versus 582. 8x for Exact Sciences Corporation — 582. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CATX: 226. 4% to $11. 75.

08

Which pays a better dividend — CATX or LNTH or AGEN or RNW or EXAS?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is CATX or LNTH or AGEN or RNW or EXAS better for a retirement portfolio?

For long-horizon retirement investors, Exact Sciences Corporation (EXAS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

12), +1669% 10Y return). Agenus Inc. (AGEN) carries a higher beta of 2. 72 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXAS: +1669%, AGEN: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CATX and LNTH and AGEN and RNW and EXAS?

These companies operate in different sectors (CATX (Healthcare) and LNTH (Healthcare) and AGEN (Healthcare) and RNW (Utilities) and EXAS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CATX is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; AGEN is a small-cap quality compounder stock; RNW is a small-cap high-growth stock; EXAS is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

CATX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

LNTH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 10%
Run This Screen
Stocks Like

AGEN

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Gross Margin > 21%
Run This Screen
Stocks Like

RNW

High-Growth Disruptor

  • Sector: Utilities
  • Market Cap > $100B
  • Revenue Growth > 18%
  • Net Margin > 5%
Run This Screen
Stocks Like

EXAS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 41%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CATX and LNTH and AGEN and RNW and EXAS on the metrics below

Revenue Growth>
%
(CATX: -100.0% · LNTH: 1.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.